Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.

× No keyword cloud information.

17 in total

1. Use of neuraminidase inhibitors in primary health care during pandemic and seasonal influenza between 2009 and 2013.

Authors: Thierry Blanchon; Félicité Geffrier; Clément Turbelin; Isabelle Daviaud; Cédric Laouénan; Xavier Duval; Bruno Lambert; Thomas Hanslik; Anne Mosnier; Catherine Leport
Journal: Antivir Ther Date: 2015-02-17

2. The Relationship Between Oseltamivir and Suicide in Pediatric Patients.

Authors: Rachel Harrington; Sruthi Adimadhyam; Todd A Lee; Glen T Schumock; James W Antoon
Journal: Ann Fam Med Date: 2018-03 Impact factor: 5.166

3. Classification of patient characteristics associated with reported adverse drug events to neuraminidase inhibitors: an applicability study of latent class analysis in pharmacovigilance.

Authors: Takuro Okada; Masayuki Hashiguchi; Satoko Hori
Journal: Int J Clin Pharm Date: 2022-09-26

4. Identifying Acute Neuropsychiatric Events in Children and Adolescents.

Authors: James W Antoon; James A Feinstein; Carlos G Grijalva; Yuwei Zhu; Emily Dickinson; Justine C Stassun; Jakobi A Johnson; Mert Sekmen; Yasas C Tanguturi; James C Gay; Derek J Williams
Journal: Hosp Pediatr Date: 2022-05-01

Review 5. COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development.

Authors: Manasi P Jogalekar; Anurag Veerabathini; Ankit B Patel
Journal: Exp Biol Med (Maywood) Date: 2021-03-23

6. Life-Threatening Abnormal Behavior Incidence in 10-19 Year Old Patients Administered Neuraminidase Inhibitors.

Authors: Yuuki Nakamura; Tamie Sugawara; Yasushi Ohkusa; Kiyosu Taniguchi; Chiaki Miyazaki; Mariko Momoi; Nobuhiko Okabe
Journal: PLoS One Date: 2015-07-01 Impact factor: 3.240

7. The inhibitory effect of kakkonto, Japanese traditional (kampo) medicine, on brain penetration of oseltamivir carboxylate in mice with reduced blood-brain barrier function.

Authors: Kousuke Ohara; Shinji Oshima; Nanami Fukuda; Yumiko Ochiai; Ayumi Maruyama; Aki Kanamuro; Akio Negishi; Seiichi Honma; Shigeru Ohshima; Masayuki Akimoto; Shingo Takenaka; Daisuke Kobayashi
Journal: Evid Based Complement Alternat Med Date: 2015-02-19 Impact factor: 2.629

8. Role of the ABCB1 Drug Transporter Polymorphisms in the Pharmacokinetics of Oseltamivir in Humans: a Preliminary Report.

Authors: Yu Jung Cha; Jong Lyul Ghim
Journal: J Korean Med Sci Date: 2017-09 Impact factor: 2.153

9. Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections.

Authors: Pranab K Mukherjee; Frank Esper; Ken Buchheit; Karen Arters; Ina Adkins; Mahmoud A Ghannoum; Robert A Salata
Journal: BMC Infect Dis Date: 2017-01-14 Impact factor: 3.090

10. A SOCS1/3 Antagonist Peptide Protects Mice Against Lethal Infection with Influenza A Virus.

Authors: Chulbul M Ahmed; Rea Dabelic; Simone Kennedy Bedoya; Joseph Larkin; Howard M Johnson
Journal: Front Immunol Date: 2015-11-11 Impact factor: 7.561